Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Michael D Ehlers
AddedMar 31, 2024
UpdatedMay 31, 2026
Michael D Ehlers

Michael D Ehlers

Founder, Intergalactic Therapeutics

Crunchbase

Michael D Ehlers's Career

Intergalactic Therapeutics
Intergalactic Therapeutics

Cambridge, MA, US

Founder
Replicate Bioscience
Replicate Bioscience

San Diego, CA, US

Board Member· Board
Ascidian Therapeutics
Ascidian Therapeutics

Boston, MA, US

Board Member· Board
Aulos Bioscience
Aulos Bioscience

Larkspur, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Michael D Ehlers's Career

Intergalactic Therapeutics
Intergalactic Therapeutics
Series A$75M412020Cambridge, MA, US
Founder

Similar to Intergalactic Therapeutics

Code BiotherapeuticsCode BiotherapeuticsHatfield, PA, USGene Therapyest. 2020Code BiotherapeuticsHatfield, PA, US · est. 2020

Code Biotherapeutics: Pioneering non-viral gene therapies for serious genetic diseases.

Series A · $85M47
Lattice TherapeuticsLattice TherapeuticsWashington, D.C., DC, USDrug Delivery, Therapeuticsest. 2021Lattice TherapeuticsWashington, D.C., DC, US · est. 2021

Lattice Therapeutics: Pioneering non-viral, precision drug delivery for transformative gene therapy.

Seed · $300k3
Interius BioTherapeuticsInterius BioTherapeuticsPhiladelphia, PA, USGene Therapyest. 2019Interius BioTherapeuticsPhiladelphia, PA, US · est. 2019

Interius: Pioneering next-gen delivery tech for cell and gene therapy advancements.

Series B · $103M60
Nextrna TherapeuticsNextrna TherapeuticsBoston, MA, USTherapeuticsest. 2020Nextrna TherapeuticsBoston, MA, US · est. 2020

NextRNA Therapeutics: Innovating RNA-directed therapeutics to combat disease-causing ncRNAs.

Series A · $56.1M33
Replicate Bioscience
Replicate Bioscience
Series A$46M202020San Diego, CA, US
Board Member· Board

Leadership at Replicate Bioscience

Andrew GeallAndrew GeallCo-Founder
Zachary HartmanZachary HartmanCo-Founder
Herbert Kim LyerlyHerbert Kim LyerlyCo-Founder
Mohit TrikhaMohit TrikhaBoard Member
Nathaniel WangNathaniel WangCo-Founder
Ascidian Therapeutics
Ascidian Therapeutics
Series A$90M452020Boston, MA, US
Board Member· Board

Leadership at Ascidian Therapeutics

Romesh SubramanianRomesh SubramanianCEO
Aulos Bioscience
Aulos Bioscience
Series A$60M122020Larkspur, CA, US
Board Member· Board

Leadership at Aulos Bioscience

Aron KnickerbockerAron KnickerbockerCEO
Micah PearlmanMicah PearlmanCo-Founder
Michael HopkinsMichael HopkinsCo-Founder
Yanay OfranYanay OfranCo-Founder

Similar to Aulos Bioscience

Alaunos TherapeuticsAlaunos TherapeuticsHouston, TX, USCancer Treatmentest. 2005Alaunos TherapeuticsHouston, TX, US · est. 2005

Alaunos Therapeutics: A global clinical-stage company specializing in TCR-T cell therapy for solid tumors.

Public · $293.4M34
Angarus TherapeuticsAngarus TherapeuticsPortola Valley, CA, USTherapeuticsest. 2018Angarus TherapeuticsPortola Valley, CA, US · est. 2018

Angarus: Innovating precise immuno-oncology therapies for a targeted and powerful cancer attack.

Series A · $11.3M75
Aurion BiotechAurion BiotechSeattle, WA, USBiotech, Therapiesest. 2021Aurion BiotechSeattle, WA, US · est. 2021

Aurion Biotech: Clinical-stage biotech firm pioneering advanced therapies to cure blindness.

Late Stage Private · $120M55
Auron TherapeuticsAuron TherapeuticsWellesley, MA, USCancer Therapiesest. 2018Auron TherapeuticsWellesley, MA, US · est. 2018

Auron Therapeutics: Pioneering cell transformation therapies for cancer treatment.

Series A · $61.4M28

Michael D Ehlers's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Michael D Ehlers

John M LeonardJohn M LeonardBoard Member · Intellia TherapeuticsMichael DetmerMichael DetmerCo-Founder · Innovative TherapeutixColin FosterColin FosterBoard Member · Ontario Bioscience Industry OrganizationDan PiacquadioDan PiacquadioFounder · TherapeuticsMichael J HigginsMichael J HigginsBoard Member · PulmatrixMichael BruceMichael BruceCEO · Exo Therapeutics